P21

What is P21 (P021)?

P21, also designated P021 and chemically identified as Ac-DGGL(A)G-NH2, is a synthetic tetrapeptide derived from amino acid residues 148–151 of the biologically active region of human ciliary neurotrophic factor (CNTF). The compound was developed in the laboratory of Professor Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities as a small-molecule mimetic of CNTF's neurogenic and neurotrophic activities. Its sequence — acetylated aspartate-glycine-glycine-leucine with an adamantylated glycine at the C-terminus — was designed to retain the neurogenic activity of the parent 11-residue peptide (Peptide 6, Ac-VGDGGLFEKKL-NH2) in a more compact, chemically stable, and blood-brain barrier (BBB)-permeable form. The C-terminal adamantylation of glycine increases the compound's lipophilicity and reduces susceptibility to exopeptidase degradation, enabling BBB penetration and oral bioavailability in preclinical rodent models.

P21 is investigated in preclinical research contexts for its capacity to modulate brain-derived neurotrophic factor (BDNF) expression, inhibit leukemia inhibitory factor (LIF) signalling, promote hippocampal neurogenesis, and attenuate tau hyperphosphorylation via the BDNF-TrkB-PI3K-AKT-GSK-3β pathway. Unlike full-length CNTF, P21 does not elicit CNTF antibody formation and is not associated with the systemic adverse effects observed with native CNTF or BDNF administration in preclinical studies. P21 is not approved by the Food and Drug Administration for human or veterinary use. It is not a dietary supplement and is not intended for human consumption or therapeutic self-administration. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties

How Does P21 Work?

P21 mediates its neurogenic and neurotrophic effects through a multi-step signalling cascade initiated by competitive inhibition of LIF signalling and culminating in GSK-3β inactivation via the BDNF-TrkB-PI3K-AKT pathway.

LIF Signalling Inhibition and BDNF Upregulation

P21 was designed to mimic the activity of endogenous CNTF by competitively inhibiting the anti-neurogenic activity of leukemia inhibitory factor (LIF) at the CNTF receptor complex. In isolated neural cell preparations and rodent in vivo models, P21 treatment is associated with increased transcription and expression of brain-derived neurotrophic factor (BDNF) in hippocampal and cortical tissues [Kazim et al., 2014]. BDNF upregulation promotes the survival, maturation, and synaptic integration of newborn neurons in the dentate gyrus through TrkB receptor activation.

BDNF-TrkB-PI3K-AKT-GSK-3β Pathway

Following BDNF upregulation, TrkB receptor activation initiates the PI3K-AKT intracellular signalling cascade, leading to inhibitory phosphorylation of glycogen synthase kinase-3β (GSK-3β) at Serine 9 [Kazim et al., 2014]. GSK-3β is the primary tau kinase responsible for abnormal tau hyperphosphorylation at neurofibrillary tangle-associated sites (AT8: pSer202/pThr205; PHF1: pSer396/pSer404) observed in Alzheimer's disease transgenic models. Inactivation of GSK-3β via P21-mediated BDNF signalling results in a reduction of tau hyperphosphorylation at these major AD pathology sites in 3xTg-AD mouse preparations [Kazim et al., 2014].

Neurogenesis and Synaptic Plasticity

In 3xTg-AD and wild-type rodent models, P21 treatment is associated with enhanced dentate gyrus neurogenesis as measured by Ki-67 (cell proliferation) and DCX (doublecortin, immature neurons) immunostaining, alongside rescue of dendritic and synaptic density markers in hippocampal subregions. These neurogenic effects are observed in preclinical rodent models and are attributed to the combined effects of LIF inhibition and BDNF-mediated promotion of neural progenitor cell survival, differentiation, and integration [Bhanu et al., 2016].

Amyloid-Beta Pathway Interactions

GSK-3β inactivation also plays a role in amyloidogenic processing of amyloid precursor protein (APP). In 3xTg-AD mouse preparations treated chronically with P21, significant reductions in soluble Aβ levels have been observed, with a trend toward reduced Aβ plaque load in hippocampal CA1 regions, consistent with a reduction in Aβ generation rather than clearance mechanisms [Kazim et al., 2014].

Key Research Findings

In preclinical and in vitro research contexts, P21 has been associated with the following observations:

• Tau hyperphosphorylation reduction: Significant decrease in AT8 and PHF1 site tau phosphorylation observed in hippocampal subfields of 3xTg-AD mice following 6 and 12 months of chronic P21 dietary treatment [Kazim et al., 2014].
• Dentate gyrus neurogenesis enhancement: Increased Ki-67 and DCX-positive cell counts in dentate gyrus of P21-treated 3xTg-AD and wild-type rodent models; enhanced survival and integration of newborn neurons observed [Bhanu et al., 2016].
• Soluble Aβ reduction: Significant decrease in soluble Aβ levels in hippocampal preparations from chronically P21-treated 3xTg-AD mice; proposed mechanism is GSK-3β inhibition reducing amyloidogenic APP processing [Kazim et al., 2014].
• Cognitive performance in rodent models: Chronic P21 treatment associated with improved performance on Morris Water Maze and novel object recognition tasks in 3xTg-AD rodent models [Kazim et al., 2014].
• Cognitive ageing model: In aged rodent models (non-transgenic), P21 administration is associated with rescue of age-related cognitive decline and decreased neurogenesis in hippocampal preparations [Bolognin et al., 2014].
• Neurodevelopmental model: In the Ts65Dn mouse model of Down syndrome, early P21 treatment is associated with rescue of developmental delay and prevention of Alzheimer's-like memory deficits in preclinical model preparations. [Kazim et al., 2017; PMID: 28368015]

All findings listed above are derived from preclinical in vitro and in vivo rodent model data. No human clinical trial data have been established for P21. These observations do not constitute evidence of efficacy or safety in any human condition or organism.

What are the Potential Research Applications of P21?

In controlled laboratory environments, P21 has been investigated for the following research applications. These are observed in preclinical and in vitro contexts only and do not constitute claims of efficacy or safety in any organism.

Neurotrophic Factor Mimetic Pharmacology Studies. P21 serves as the primary research tool for investigating CNTF small-molecule mimetic activity in isolated neural cell preparations. It is employed in receptor binding assays, BDNF expression studies, and LIF pathway competition experiments to characterise the relationship between CNTF receptor engagement and downstream neurotrophic signalling.

Tau Hyperphosphorylation and Tauopathy Research. In 3xTg-AD and other tauopathy rodent model preparations, P21 is investigated for its capacity to modulate tau kinase activity via the BDNF-TrkB-PI3K-AKT-GSK-3β cascade. Research examines site-specific phosphorylation patterns at neurofibrillary tangle-associated epitopes and the relationship between GSK-3β inhibition and tau pathology attenuation.

Hippocampal Neurogenesis and Neural Progenitor Cell Studies. P21 is employed in dentate gyrus neurogenesis investigations using Ki-67, DCX, and NeuN immunostaining protocols in rodent and in vitro neural stem cell preparations. Research examines LIF pathway competition as a mechanism for enhancing neural progenitor cell proliferation, differentiation, and synaptic integration.

Alzheimer's Disease Preclinical Model Research. In 3xTg-AD mouse model preparations, P21 is used to investigate the simultaneous modulation of Aβ, tau, and synaptic plasticity pathways. The compound's blood-brain barrier permeability and oral bioavailability in rodents make it a useful tool for chronic in vivo treatment paradigms examining multi-target neurodegenerative pathway modulation.

Neurodegenerative Disease Model Comparators. P21 is employed in comparative studies alongside full-length CNTF, BDNF, and recombinant neurotrophic factor preparations to characterise the activity profile of small-molecule peptide mimetics relative to parent proteins in neuronal cell culture and in vivo CNS models.

What are the Potential Side Effects of P21?

Researchers in preclinical and in vitro settings have noted the following observations. Long-term safety profiles in humans have not been established, and no clinical trial data exist for P21.

• No weight loss, tumour formation, or signs of pain observed in 3xTg-AD or wild-type mice treated chronically with P21 (60 nmol/g feed) for 18 months in published preclinical studies
• No significant changes in general physical state, grooming, posture, or clasping reflex were observed in P21-treated rodents at chronic dosing levels in published studies
• Transient body weight increases reported in both 3xTg-AD and wild-type mice during P21 treatment; mechanism not characterised
• Antibody formation against P21 has been proposed as a theoretical adverse event based on its peptide nature; no immune reaction to P21 has been reported in preclinical studies to date
• Unlike full-length CNTF administration, P021 has not been associated with the CNTF antibody formation or systemic adverse effects observed with native cytokine administration in preclinical models
• No human safety or tolerability data have been established for P21. These observations are derived from rodent experimental systems and should not be extrapolated to human or animal outcomes.

Risk & Handling

Handling Precautions

P21 should only be handled by trained laboratory personnel familiar with synthetic neuropeptide research compounds. Appropriate personal protective equipment is required: nitrile gloves, a laboratory coat, and eye protection at a minimum. When working with the lyophilized powder, use within a laminar flow cabinet or clean area to avoid inhalation of particulate matter. Avoid aerosol generation during reconstitution. The adamantylated C-terminus increases lipophilicity; avoid prolonged contact with surfaces that adsorb hydrophobic molecules.

Exposure Risks

Risk Tier: LOW–MODERATE

P21 has demonstrated a generally benign acute and chronic safety profile in rodent preclinical studies at concentrations investigated in published research. No acute toxicity findings have been reported at standard research doses. The compound's CNS-active mechanism — BDNF pathway modulation and GSK-3β inhibition — means that laboratory personnel should be aware of potential neurobiological activity in the event of inadvertent systemic exposure, though such effects have not been characterised in humans. No human safety or tolerability data have been established for P21.

Storage

• Lyophilized form: Store at −20°C in original sealed, light-protected container with desiccant
• Reconstituted form: Store at 4°C; use within 48–72 hours of reconstitution
• Do not subject to repeated freeze-thaw cycles; peptide and adamantyl conjugate integrity may be compromised
• Protect from prolonged light exposure and moisture
• P21 demonstrates high stability in aqueous media (>90% gastric stability, >95% intestinal stability at 37°C, preclinical data)

Frequently Asked Questions

Q: What is P21, and what is it investigated for in research? A: P21 (P021, Ac-DGGL(A)G-NH2) is a synthetic tetrapeptide CNTF mimetic investigated in preclinical research contexts for BDNF pathway modulation, hippocampal neurogenesis enhancement, tau hyperphosphorylation attenuation, and Alzheimer's disease pathway research in rodent models. It is not approved by the FDA for human use and is intended strictly for laboratory and research purposes.

Q: How does P21 differ from full-length CNTF? A: Full-length CNTF (22.8 kDa) cannot efficiently cross the blood-brain barrier, has poor plasma stability, and elicits CNTF antibody formation upon systemic administration in preclinical and clinical studies. P21 is a 578.67 g/mol tetrapeptide that retains neurogenic and neurotrophic activity of the CNTF active region while being BBB-permeable, orally bioavailable, and metabolically stable in preclinical rodent models without antibody formation or the systemic adverse effects associated with native CNTF.

Q: What is the half-life of P21 in preclinical models? A: In mouse plasma studies, P21 has a half-life of over 3 hours. In in vitro stability assays, the compound demonstrates >90% stability in artificial gastric juice at 30 minutes and >95% stability in artificial intestinal fluid at 120 minutes at 37°C. These figures are derived from rodent and in vitro preclinical data and do not represent human pharmacokinetic data.

Q: How should P21 be stored to maintain stability? A: Lyophilized P21 should be stored at −20°C in a sealed, light-protected container with desiccant. Once reconstituted, the working solution should be stored at 4°C and used within 48–72 hours. Repeated freeze-thaw cycles are not recommended as they may compromise peptide and adamantyl group integrity. P21 demonstrates high intrinsic stability in aqueous media; protect from prolonged light exposure.

Q: What toxicity observations have been reported for P21 in preclinical studies? A: Chronic dietary administration of P21 in 3xTg-AD and wild-type mice for up to 18 months has not produced weight loss, tumour formation, motor deficits, or signs of pain in published preclinical studies. No immune reactions to P21 have been reported. No human safety or tolerability data have been established. Preclinical observations should not be extrapolated to human or animal outcomes.

Q: What are the key pathway mechanisms P21 modulates in preclinical models? A: P21 competitively inhibits LIF signalling at the CNTF receptor complex, leading to upregulation of BDNF expression in hippocampal and cortical tissues. Increased BDNF activates TrkB receptors, initiating PI3K-AKT signalling and inhibitory phosphorylation of GSK-3β at Serine 9. GSK-3β inactivation reduces tau hyperphosphorylation at AD pathology-associated sites and attenuates amyloidogenic APP processing in preclinical 3xTg-AD model preparations. Visit RCD Bio to explore our full research compound catalog.